

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome	INTRONA MARTINO
Indirizzo (lavoro)	UOS Centro di Terapia Cellulare “G. Lanzani”, ASST Papa Giovanni XXIII, Bergamo, Italia
Telefono	Lavoro: 035-2278636
Fax	035-2278674
E-mail	mintrona@asst-pg23.it
Nazionalità	Italiana
Sesso	M
Data di nascita	16.01.1955

ESPERIENZA LAVORATIVA

INCARICO ATTUALE

- | | |
|----------------|---|
| | Responsabile della UOS Centro di Terapia Cellulare “G. Lanzani”, UOC Ematologia, ASST Papa Giovanni XXIII |
| • 2017 ad oggi | Docente per il corso di Cell and Molecular Biology del corso di laurea Medicine and Surgery, Università Milano-Bicocca |
| • 2007 ad oggi | Università Milano-Bicocca, Ph.D. Program in Translational and Molecular Medicine (DIMET), Lecturer and tutor for the PhD program |
| • 2005 ad oggi | Dirigente Medico dell’USS Centro di Terapia Cellulare “G. Lanzani” (“Cell Factory” autorizzata AIFA) – USC Ematologia, Azienda Socio Sanitaria Territoriale Ospedale Papa Giovanni XXIII Bergamo, Italia. |
| • 2003-2005 | Responsabile Scientifico del Laboratorio di Terapia Cellulare “G. Lanzani” – USC Ematologia, Bergamo, Italia. |
| • 1995-2003 | Capo del Laboratorio di Immunoematologia Molecolare del Dipartimento di Immunologia e Biologia Cellulare presso l’Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italia. |
| • 1991-1995 | Capo dell’unità di Differenziazione Molecolare del Dipartimento di Immunologia e Biologia Cellulare presso l’Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italia. |
| • 1989-1990 | Ricercatore, Dipartimento di Immunologia Umana del Dipartimento di Immunologia e Biologia Cellulare presso l’Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italia. |

- 1986- 1988 Borsista Ricercatore, Dipartimento di Differenziazione del EMBL (European Molecular Biology Laboratory), Heidelberg, Germania
 - 1984-1986 Borsista Ricercatore, Dipartimento di Medicina, Divisione di Ematologia/Oncologia della Duke University Medical School, Durham, North Carolina, U.S.A.
 - 1980-1984 Borsista Ricercatore, Laboratorio di Immunologia del Dipartimento di Immunologia e Biologia Cellulare presso l'Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italia.
- **Nome e indirizzo del datore di lavoro**
 Azienda Socio Sanitaria Territoriale Ospedale Papa Giovanni XXIII
 Piazza OMS 1 – 24127 Bergamo, Italia
- **Tipo di azienda o settore**
 Azienda Ospedaliera pubblica
- **Tipo di impiego**
 Dirigente Medico
 Qualified Person (Decreto AIFA N. aIDT-49/2005) e Responsabile del Centro di Terapia Cellulare "G. Lanzani" (deliberazione n. 735 30/4/2014 Azienda Ospedaliera Papa Giovanni XXIII)
- **Principali mansioni e responsabilità**
 Come Qualified Person sono state ottenute le seguenti approvazioni AIFA alla produzione GMP:
 - aAMM-28/2017
 - aM-57/2016
 - aAMM-123/2014
 - aM-62/2014
 - aM-155/2010
 - aM-189/2008
 - aM-144/2007
 Come responsabile del laboratorio di processazione cellulare, è stata ottenuta la certificazione JACIE (Joint Accreditation Committee ISCT EBMT) n°562 23/02/2016 per la quale, il laboratorio risulta iscritto nel registro europeo dei tessuti e prodotti cellulari (EU Tissue Establishment Compendium) (Codice IT000076)

ISTRUZIONE E FORMAZIONE

- 2012 Ottenimento della idoneità nazionale a Professore Ordinario in Patologia Generale
- 1984 Specializzazione in Immunologia e Allergologia – Università di Bari – Italia (con lode)
- 1980 Laurea in Medicina e Chirurgia- Università di Bari – Italia (110/110 e lode)

CAPACITÀ E COMPETENZE PERSONALI

PRIMA LINGUA **ITALIANO**

ALTRE LINGUE

INGLESE

ECCELLENTE

ECCELLENTE

ECCELLENTE

FRANCESE

BUONO

BUONO

BUONO

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale
- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

CAPACITÀ E COMPETENZE RELAZIONALI	COORDINAZIONE DI GRUPPI DI RICERCA DAL 1984 ATTIVITA' DI INSEGNAMENTO A LIVELLO UNIVERSITARIO TUTOR NELL'AMBITO DEL PROGRAMMA DI PHD DIMET; UNIVERSITA' MILANO BICOCCA
CAPACITÀ E COMPETENZE ORGANIZZATIVE	RESPONSABILE LABORATORIO DI DAL 1984, RESPONSABILE CELL FACTORY DAL 2003, RACCOLTA FONDI DI RICERCA PER L'ATTIVITÀ SCIENTIFICA E LA CELL FACTORY
CAPACITÀ E COMPETENZE TECNICHE	BIOLOGIA MOLECOLARE, BIOLOGIA CELLULARE, MODELLI ANIMALI, IMMUNOLOGIA, EMATOLOGIA SPERIMENTALE, TERAPIA CELLULARE E GENICA CON VETTORI RETROVIRALI. QUALIFIED PERSON OFFICINA FARMACEUTICA GMP
CAPACITÀ E COMPETENZE ARTISTICHE	CHITARRA ACUSTICA 6 CORDE VOCE
ALTRE CAPACITÀ E COMPETENZE	AUTORE DI OLTRE 190 PUBBLICAZIONI SCIENTIFICHE SU RIVISTE INTERNAZIONALI CON REFERAGGIO

JOURNALS-RIVISTE:

1. Allavena P, **Introna M**, Mangioni C and Mantovani A (1981). Inhibition of natural killer activity by tumor-associated lymphoid cells from ascitic ovarian carcinomas. *J. Natl. Cancer Inst.* 67: 319-325.
2. **Introna M**, Allavena P, Spreafico F and Mantovani A (1981). Inhibition of human natural killer activity by cyclosporin A. *Transplantation* 31: 113-116.
3. Mantovani A, Sessa C, Peri G, Allavena P, **Introna M**, Polentarutti N and Mangioni C (1981). Intraperitoneal administration of *Corynebacterium parvum* in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor-associated macrophages and NK cells. *Int. J. Cancer* 27: 437-446.
4. Allavena P, **Introna M**, Sessa C, Mangioni C and Mantovani A (1982). Interferon effects on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells. *J. Natl. Cancer Inst.* 68: 555-562.
5. Bordignon C, Villa F, Allavena P, **Introna M**, Biondi A, Avallone R and Mantovani A (1982). Inhibition of natural killer activity by human bronchoalveolar macrophages. *J. Immunol.* 129: 587-591.
6. Bordignon C, Villa F, Vecchi A, Giavazzi R, **Introna M**, Avallone R and Mantovani A (1982). Natural cytotoxic activity in human lungs. *Clin. Exp. Immunol.* 47: 437-444.
7. **Introna M**, Allavena P, Biondi A, Colombo N, Villa A and Mantovani A (1983). Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ. *J. Natl. Cancer Inst.* 70: 21-26.
8. **Introna M** and Mantovani A (1983). Natural killer cells in human solid tumor. *Cancer Metast Rev*, 2: 337-350.
9. Colotta F, Rambaldi A, Colombo N, Tabacchi L, **Introna M** and Mantovani A (1983). Effect of streptococcal preparation (OK432) on natural killer activity of tumor-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumor cells. *Br. J. Cancer* 48: 515-525.
10. Biondi A, Landonfo S, Fumarola D, Polentarutti N, **Introna M** and Mantovani A (1984). Evaluation of absorption on *Ilymus amebocyte* lysate to remove contaminating endotoxin from interferon and lymphokine preparations. *J. Immunol. Methods*, 66: 103-112.
11. Lazzarin A, Galli M, **Introna M**, Negri C, Mantovani A, Mella L, Ferrante P, Parravinci C, Trombini M, Aiuti F, Moroni M and Zanussi C (1984). Outbreak of persistent, unexplained, generalized lymphadenopathy with immunological abnormalities in drug addicts in Milan. *Infection* 6, 12: 372-376.
12. Bottazzi B, **Introna M**, Allavena P, Villa A and Mantovani A (1985). In vitro migration of human large granular lymphocytes. *J. Immunol* 134: 2316-2321.
13. Poli G, **Introna M**, Zanaboni F, Peri G, Carbonari M, Aiuti F, Lazzarin A, Cultraro D, Moroni M and Mantovani A (1985). Natural killer cells in intravenous drug abusers with LAS (lymphadenopathy syndrome). *Clin. Exp. Immunol.* 62: 128-135.
14. Poli G, Bottazzi B, Acero R, Bersani L, Rossi V, **Introna M**, Lazzarin A, Galli M and Mantovani A (1985). Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired

immunodeficiency syndrome: selective impairment of chemotaxis. Clin. Exp. Immunol. 62: 156-162.

15. Rambaldi A, **Introna M**, Colotta F, Landolfo S, Colombo N, Mangioni C and Mantovani A (1985). Intraperitoneal administration of IFN B in ovarian cancer patients. Cancer 56: 294-301.

16. Rambaldi A, Rossi V, Allavena P, **Introna M**, Landolfo S, Bassan R, Barbui T and Mantovani A (1986). Lymphokine production of T lymphoproliferative disorders. Scandinavian J. Immunol. 23: 183-188.

17. Allavena P, **Introna M**, Rambaldi A, Zanaboni F, Rossini S, Villa A, Bassan R, Barbui T and Mantovani A (1986). Induction of cytotoxicity by interleukin 2 in T-lymphoproliferative disorders. Int. J. Cancer 37: 27-33.

18. Bottazzi B, Rambaldi A, **Introna M**, Merendino A, Bassan R, Viero P, Barbui T and Mantovani A (1986). Migratory capacity of large granular lymphocyte from lymphoproliferative disorders. Natural Immunity 5: 19-27.

19. Bassan R, **Introna M**, Rambaldi A, Viero P, Chisesi T, Cortellazzo S, Mantovani A and Barbui T (1986). Clinical and laboratory heterogeneity of large granular lymphocyte proliferative disorders. Scand. J. Hemat. 37: 91-96.

20. **Introna M**, Hamilton TA, Kaufman RE, Strassman A, Adams DO and Bast RC Jr (1986). Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J. Immunol. 137: 2711-2715.

21. **Introna M**, Bast RC Jr, Johnston PA, Adams DO and Hamilton TA (1987). Homologous and heterologous desensitization of proto-oncogene c-fos expression in murine peritoneal macrophages. J. Cell. Physiol. 131: 36-42.

22. **Introna M**, Bast RC, Tannenbaum CS, Hamilton TA and Adams DO (1987). The effect of LPS on expression of the "early" competence genes JE and KC in murine peritoneal macrophages. J. Immunol. 138: 3891-3896.

23. Koerner TJ, Hamilton TA, **Introna M**, Tannenbaum CS, Bast RC and Adams DO (1987). The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. Bio. Bio. Res. Comm. 149: 969-974.

24. Frykberg L, Metz T, Brady G, **Introna M**, Beug H, Vennstrom B and Graf T (1988). A point mutation in the DNA binding domain of the v-myb oncogene of E26 virus confers temperature sensitivity for transformation of myelomonocytic cells. Oncogene Research 3: 313-322.

25. Golay J, **Introna M** and Graf T (1988). A single point mutation in the v-ets oncogene affects both erythroid and myelomonocytic cell differentiation. Cell 55: 1147-1158.

26. **Introna M**, Golay J, Frampton J, Nakano T, Ness S and Graf T (1990). Mutations in v- myb alter the differentiation of myelomonocytic cells transformed by the oncogene. Cell 63: 1287-1297.

27. Fuerstenberg S, Beug H, **Introna M**, Khazaie K, Munoz A, Ness S, Nordstrom K, Sap J, Stanley I, Zenke M and Vennstrom B (1990). Ectopic expression of the erythrocyte band 3 anion exchange protein using a new avian retrovirus vector. J. Virol. 64: 5891-5902.

28. Golay J, Passerini F and **Introna M** (1991). A simple and rapid method to analyze specific mRNAs from few cells in a semi-quantitative way using the polymerase chain reaction. PCR Methods and Applications 1: 144-145.

29. Golay J, Capucci A, Arsura M, Castellano M, Rizzo V and **Introna M** (1991). The expression of c-myb and B-

myb but not A-myb correlates with proliferation in human haematopoietic cells. *Blood* 77: 149-158.

30. Castellano M, Golay J, Mantovani A and **Introna M** (1992). Detection of a transcriptional block in the first intron of the human c-myb gene. *Int. J. Clin. Lab. Res.* 22: 159-164.

31. Arsura M, **Introna M**, Passerini F, Mantovani A and Golay J (1992). B-myb antisense oligonucleotides inhibit proliferation of human haematopoietic cell lines. *Blood* 79: 2708-2716.

32. Golay J, Cusmano G and **Introna M** (1992). Independent regulation of c-myc, B-myb and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. *J. Immunol.* 149: 300-308.

33. Breviario F, D'Aniello E, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, Della Valle G, Dejana E, Mantovani A and **Introna M** (1992). Interleukin-1 inducible genes in endothelial cells: cloning of a new gene related to C-Reactive Protein and Serum Amyloid P component. *J. Biol. Chem.* 267: 22190-22197.

34. D'Aniello EM, Breviario F, Padura IM, Lampugnani MG, Dejana E, Mantovani A and **Introna M** (1993). Interleukin-1 and Tumour Necrosis Factor induce transient expression of an inhibitor of nuclear factor- κ B in endothelial cells. *Endothelium*, 1: 161-165.

35. **Introna M**, Breviario F, D'Aniello EM, Golay J, Dejana E and Mantovani A (1993). IL-1 inducible genes in human umbilical vein endothelial cells. *European Heart J.* 14: 78-81.

36. **Introna M**, Luchetti M, Castellano M, Arsura M and Golay J (1994). The myb oncogene family of transcription factors: potent regulators of haematopoietic cell proliferation and differentiation. *Semin. Cancer Biol.* 5: 113-124.

37. Arsura M, Luchetti MM, Erba E, Golay J, Rambaldi A and **Introna M** (1994). Dissociation between p93 B-myb and p75 c-myb expression during proliferation and differentiation of human myeloid cell lines. *Blood*, 83:1778-1790.

38. Golay J, Erba E, Bernasconi S, Peri G, and **Introna M** (1994). The A-myb gene is highly expressed in tonsillar CD38⁺, CD39⁻, sIgM⁻ B lymphocytes and in Burkitt's lymphoma cell lines. *J. Immunol*, 153: 543-553.

39. Vidal Alles V, Bottazzi B, Peri G, Golay J, **Introna M** and Mantovani A (1994). Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. *Blood*, 84: 3483-3493.

40. Golay J, Loffarelli L, Luppi M, Castellano M and **Introna M** (1994). The human A-myb protein is a strong activator of transcription. *Oncogene* 9: 2469-2479.

41. Breviario F, Caveda L, Corada M, Martin-Padura I, Navarro P, Golay J, **Introna M**, Gulino D, Lampugnani MG and Dejana E (1995). Functional properties of human vascular endothelial cadherin (7B4/cadherin 5), an endothelium-specific cadherin. *Arterioscler. Thromb. Vasc. Biol*, 15: 1229-1239.

42. Muzio M, Polentarutti N, Sironi M, Poli G, De Gioia L, **Introna M**, Mantovani A, Colotta F (1995). Cloning and characterization of a new isoform of the interleukin-1 (IL-1) receptor antagonist (IL-1ra), *J. Exp. Med.*, 182: 623-628..

43. Golay J, Luppi M, Songia S, Palvarini C, Lombardi L, Aiello A, Delia D, Biondi A, Barbui T, Rambaldi A, **Introna M** (1996). Expression of A-myb, but not c-myb, and B-myb, is restricted to Burkitt's lymphoma, sIg⁺ B-acute lymphoblastic leukemia and a subset of chronic leukemias. *Blood*, 87: 1900-1911.

44. Sambo P, Fadlon EJ, Sironi M, Matteucci C, Introna M, Mantovani A, Colotta F (1996). Reactive oxygen intermediates cause rapid release of the IL-1 decoy receptor from human myelomonocytic cells. *Blood*, 87: 1682-1686.
45. Locati M, Lamorte G, Luini W, Introna M, Bernasconi S, Mantovani A, Sozzani S (1996). Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A2. *J. Biol. Chem*, 271: 6010-6016.
46. **Introna M**, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzi B, Peri G, Breviario F, Salmona M, De Gregorio L, Dragani TA, Srinivasan N, Blundell TL, Hamilton TA, Mantovani A (1996). Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. *Blood* 87: 1862-1872.
47. Golay J, Basilico L, Loffarelli L, Songia S, Broccoli V, **Introna M** (1996). Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. *Int. J. Clin. Lab. Res*, 26: 24-32.
48. Colotta F, Saccani S, Giri JG, Dower SK, Sims JE, **Introna M**, Mantovani A (1996). Regulated expression and release of the Interleukin 1 decoy receptor in human mononuclear phagocytes. *J. Immunol*, 156: 2534-2541.
49. Re F, Sironi M, Muzio M, Matteucci C, Introna M, Orlando S, Penton-Rol G, Dower SK, Sims JE, Colotta F, Mantovani A (1996). Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. *J. Exp. Med*, 183: 1841-1850.
50. Piccinini G, Luchetti MM, Caniglia ML, Carossino AM, Montroni M, **Introna M**, Gabrielli A (1996). C-myb proto-oncogene is expressed by quiescent scleroderma fibroblasts and, unlike B-myb gene, does not correlate with proliferation. *J. Invest. Dermat*, 106, 1-6.
51. Mantovani A, Muzio M, Ghezzi P, Colotta F, **Introna M** (1996). Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor. *Int. J. Clin. Lab. Res*. 26: 7-14.
52. Golay J, Facchinetti V, Ying G, **Introna M** (1997). The A-myb transcription factor in neoplastic and normal B cells. *Leukemia and Lymphoma*, 26: 271-279.
53. Basile A, Sica A, D'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, **Introna M** (1997). Characterization of the promoter for the human long pentraxin ptx3: role of NF- κ B in TNF- α and IL-1 β regulation. *J. Biol. Chem*, 272: 8172-8178.
54. Mantovani A, Bussolino F, **Introna M** (1997). Cytokine regulation of endothelial cell function: from molecular level to the bed site. *Immunol. Today* 18: 231-239.
55. Caslini C, Spinelli O, Cazzaniga G, Golay J, De Gioia L, Pedretti A, Breviario F, Amaru R, Barbui T, Biondi A, **Introna M** and Rambaldi A (1997). Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. *Genomics* 42: 268-277.
56. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D'Ettore C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, **Introna M**, Mantovani A (1997). Multimer formation and ligand recognition by the long pentraxin PTX3: similarities and differences with the short pentraxins C reactive protein and serum amyloid P component. *J. Biol. Chem*. 272: 32817-32823.
57. Vouret-Craviari V, Matteucci C, Peri G, Poli G, **Introna M**, Mantovani A (1997). Expression of the long pentraxin PTX3 by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. *Infection and Immunity* 65: 1345-1350.

58. Orlando S, Matteucci C, Fadlon EJ, Buurman WA, Bardella MT, Colotta F, **Introna M**, Mantovani A (1997). TNF- α , unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. *J. Immunol.* 158: 3861-3868.
59. Polentarutti N, Allavena P, Bianchi G, Giardino G, Basile A, Sozzani S, Mantovani A, **Introna M** (1997). IL-2 regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4 kb transcript containing CCR2B and CCR2A sequences. *J. Immunol.* 158: 2689-2694.
60. Tedesco F, Pausa M, Nardon E, **Introna M**, Mantovani A, Dobrina A (1997). The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. *J. Exp. Med.* 185: 1619-1627.
61. Facchinetti V, Loffarelli L, Schreek S, Oelgeschlager M, Lusher B, **Introna M**, Golay J (1997). Regulatory domains of the A-myb transcription factor and its interaction with the CBP/p300 adaptor molecules. *Biochem. J.* 324: 729-736.
62. Golay J, Broccoli V, Borleri GM, Erba E, Faretta M, Basilico L, Ying GG, Piccinini G, Shapiro LH, Lovric J, Nawrath M, Molling K, Rambaldi A and **Introna M** (1997). Redundant functions of B-myb and c-myb in differentiating myeloid cells, *Cell Growth and Diff.* 8: 1305-1316.
63. **Introna M** and Mantovani A (1997). Early activation signals in endothelial cell; stimulation by cytokines. *Arterioscl. Thromb. Vasc. Biol.* 17: 423-428.
64. Penton Rol G, Polentarutti N, Sironi M, Sacconi S, **Introna M**, Mantovani A (1997). Gene transfer-mediated expression of physiological numbers of the type II decoy receptor in a myelomonocytic cellular context dampens the response to IL-1, *European Cytokine Network.* 8: 265-269.
65. Sozzani S, **Introna M**, Bernasconi S, Polentarutti N, Cinque P, Poli G, Sica A, and Mantovani A (1997). MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. *J. Leuk. Biol.* 62: 30-33.
66. Ying GG, Arsura M, **Introna M** and Golay J (1997). The DNA binding domain of the A-myb transcription factor is responsible for its B cell specific activity and binds to a B cell 110 kD nuclear protein. *J. Biol. Chem.* 272, 40, 24921-24926.
67. Mantovani A, Sozzani S, Vecchi A, **Introna M**, Allavena P (1997). Cytokine activation of endothelial cells: new molecules for an old paradigm. *Thrombosis and Haemostasis.* 78: 406-414.
68. Polentarutti N, **Introna M**, Sozzani S, Mancinelli R, Mantovani G, Mantovani A (1997). Expression of monocyte chemotactic protein-3 in human monocytes and endothelial cells. *European Cytokine Network* 8: 271-274.
69. Golay J, Broccoli V, Lamorte G, Bifulco C, Parravicini C, Pizzey A, Thomas NS, Delia D, Ferrauti P, Vitolo D, **Introna M** (1998). The A-myb transcription factor is a marker of centroblasts in vivo. *J. Immunol.* 160: 2786-2793.
70. Polentarutti N, Picardi G, Basile A, Cenuales S, Rivolta A, Matteucci C, Peri G, Mantovani A, **Introna M** (1998). Interferon γ inhibits expression of the long pentraxin PTX3 in human monocytes and endothelial cells. *European J. Immunol.* 28: 496-501.
71. Piccinini G, Golay J, Flora A, Songia S, Luchetti M, Gabrielli A, **Introna M** (1999). C-myb, but not B-myb, upregulates type I collagen gene expression in human fibroblasts. *J. Invest. Dermatol.* 112: 191-196.

72. **Introna M**, Barbui AM, Golay J, Bambacioni F, Schirò R, Bernasconi S, Breviario F, Erba E, Borleri G, Barbui T, Biondi A and Rambaldi A (1998). Rapid retroviral infection of human hematopoietic cells of different lineages: efficient transfer in fresh T cells. *Br. J. Haematol.* 103: 449-461
73. Muzio M, Polentarutti N, Facchetti F, Peri G, Doni A, Sironi M, Transidico P, **Introna M**, Mantovani A (1999). Characterisation of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. *Eur. J. Immunol.* 29: 781-788.
74. Penton-Roll G, Orlando S, Polentarutti N, Bernasconi S, Muzio M, Sims J.E, **Introna M**, Mantovani A. (1999). Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. *J. Immunol.* 162: 2931-2938.
75. **Introna M** and Golay J. (1999). How can oncogenic transcription factors cause cancer: a critical review of the myb story. *Leukemia* 13: 1301-1306.
76. Luchetti M.M, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, Fratini M, Fraticelli P, Sambo P, Di Loreto C, Doni A, **Introna M**, Gabrielli A. (2000). Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). *Clin. Exp. Immunol.* 119: 196-202.
77. Ying G.G, Proost P, van Damme J, Bruschi M, **Introna M**, Golay J. (2000). Nucleolin, a novel functional partner for the myb transcription factor family that regulates their activity. *J. Biol. Chem.* 275: 4152-4158.
78. Peri G, **Introna M**, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni A.P, Moccetti T, Metra M, Cas L.D, Ghezzi P, Sipe J.D, Re G, Olivetti G, Mantovani A, Latini R. (2000). PTX3, a prototypic long pentraxin, is an early indicator of acute myocardial infarction in humans. *Circulation* 102: 636-641.
79. Heckman CA, Mehem JW, Golay J, **Introna M** and Boxer LM (2000). A-myb upregulates bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. *J. Biol. Chem.* 275: 6499-6508.
80. **Introna M**, Barbui A.M, Bambacioni F, Casati C, Gaipa G, Borleri G.M, Bernasconi S, Barbui T, Golay J, Biondi A, Rambaldi A. (2000). Genetic modification of human T cells with CD20; a strategy to purify and lyse transduced cells with anti-CD20 antibodies. *Human Gene Ther.* 11: 611-620.
81. Facchinetti V, Lopa R, Spreafico F, Bolognese F, Mantovani T, Tavner F, R, Watson R, **Introna M**, Golay J. (2000). Isolation and characterisation of the human A-myb promoter: regulation by NF-Y and Sp1. *Oncogene* 19: 3931-3940.
82. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G.-M, Bernasconi S, Tedesco F, Rambaldi A, **Introna M** (2000). Biological response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. *Blood* 95: 3900-3908
83. Arsura M, Hofmann CS, Golay J, **Introna M** and Sonenshein GE (2000). A-myb rescues murine B cell lymphomas from IgM-receptor-mediated apoptosis through c-myc transcriptional regulation. *Blood* 96: 1013-1020.
84. Polentarutti N, Bottazzi B, Di Santo E, Blasi E, Agnello D, Ghezzi P, **Introna M**, Bartfai T, Richards G, Mantovani A. (2000). Inducible expression of the long pentraxin PTX3 in the central nervous system. *J. Neuroimmunol.* 106: 87-94.
85. Biagi E, Bambacioni F, Gaipa G, Casati C, Golay J, Biondi A, **Introna M** (2001). Efficient retroviral transduction of primary human acute myelogenous and lymphoblastic leukaemia cells. *Haematologica* 86: 13-16.

86. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, **Introna M** (2001). CD20 levels determine the in vitro susceptibility to Rituximab and complement of B-chronic lymphocytic leukaemia: further regulation by CD55 and CD59. *Blood*: 98:3383-3389.
87. Di Gaetano N, Xiao Y.M, Erba E, Bassan R, Rambaldi A, Golay J, **Introna M**. (2001). Synergism between Fludarabine and Rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. *Br. J. Haematol*: 114:800-809.
88. Bambacioni F, Casati C, Serafini M, Manganini M, Golay J, **Introna M** (2001). Lentiviral vectors show dramatically increased efficiency of transduction of human leukaemia cell lines. *Haematologica* 86: 1095-1096.
89. Agnello D, Scanziani E, Di Giancamillo M, Leoni F, Modena D, Mascagni P, **Introna M**, Ghezzi P, Villa P. (2002). Preventive administration of Mycobacterium tuberculosis 10-kDa heat shock protein (hsp10) suppresses adjuvant arthritis in Lewis rats. *International Immunopharmacology* 2:463-474.
90. Manganini M, Serafini M, Bambacioni F, Casati C, Erba E, Follenzi A, Naldini L, Bernasconi S, Gaipa G, Rambaldi A, Biondi A, Golay J, **Introna M** (2002). A Hiv-1 pol gene derived sequence increases the efficiency of transduction of human non dividing monocytes and T lymphocytes by lentiviral vectors. *Human Gene Ther.* 13:1793-1807
91. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, **Introna M** (2002). AIDS associated lymphoma are efficiently lysed through complement dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) by Rituximab. *Br. J. Haematol.* 119: 923-929.
92. Todisco E, Gaipa G, Biagi E, Bonamino M, Gramigna R, **Introna M** and Biondi A (2002). CD40 ligand-stimulated B-cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T-cells in childhood acute lymphoblastic leukemia. *Leukaemia* 16: 2046-54.
93. Cerny T, Borisch B, **Introna M**, Johnson P, Rose A.L. (2002). Mechanism of action of rituximab. *Anticancer Drugs* 13:S3-10.
94. Luchetti M, Paroncini P, Majlingova P, Frampton J, Mucenski M, Svegliati Baroni S, Sambo P, Golay J, **Introna M**, Gabrielli A (2003). Characterisation of the c-myc-responsive region of the human type I collagen alpha 2 chain gene. *J. Biol. Chem.* 278: 1533-1541.
95. Bonini C, Grez M, Traversari C, Ciceri F, Markt S, Ferrari G, Dinuer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeck A, Apperley J, Ebeling S, Martens A, Kolb H.J, Weber M, Lotti F, Grande A, Weissinger E, Bueren J.A, Lamana M, Falkenburg J.H, Heemskerk M.H, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, **Introna M**, Slavin S, Greenberg P.D, Bregni M, Mavilio F, Bordignon C. (2003). Safety of retroviral gene marking with truncated NGF receptor. *Nature Med.* 9:367-369.
96. **Introna M**, Golay J, Barbui T (2003). Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura. *Haematologica* 88:482-484.
97. Amico D, Barbui A, Erba E, Rambaldi A, **Introna M**, Golay J (2003). Differential response to human acute myeloid leukaemia cells to Gemtuzumab Ozogamicin (Mylotarg) in vitro. Role of Chk1 and chk2 phosphorylation and Caspase 3. *Blood*, 101:4589-4597.
98. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Golay J, **Introna M** (2003). Complement activation determines the therapeutic activity of rituximab in vivo. *J. Immunol.* 171:1581-7.

99. Chiodini B, Barlera S, Franzosi M.G, Beceiro V, **Introna M**, Tognoni G (2003). APO B gene polymorphisms and coronary artery disease: a meta-analysis. *Atherosclerosis* 167:355-366.
100. Chieppa M, Bianchi G, Doni A, Del Prete A, Sironi M, Laskarin G, Monti P, Piemonti L, Biondi A, Mantovani A, **Introna M**, Allavena P (2003). Croos-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. *J. Immunol.* 171:4552-4560
101. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, **Introna M** (2003). The rituximab-mediated antibody dependent cellular cytotoxicity agaisnst neoplastic B cells is greatly stimulated by IL-2. *Haematologica* 88:1002-12
102. Serafini M, Bonamino M, Golay J, **Introna M** (2004). Elongation factor 1 (EF1-alpha) promoter in a lentiviral backbone improves the CD20 suicide gene expression in human primary T lymphocytes allowing efficient Rituximab-mediated lysis. *Haematologica* 89:86-95.
103. Bonamino M, Serafini M, D'Amico G, Gaipa G, Todisco E, Bernasconi S, Golay J, Biondi A, **Introna M**, (2004). Functional transfer of CD40L gene in human B cell precursor ALL blasts by second generation SIN lentivectors, *Gene Therapy*, 11:85-93
104. Serafini M, Manganini M, Borleri G.M, Bonamino M, Imberti L, Biondi A, Golay J, Rambaldi A, **Introna M** (2004). Characterization of CD20 transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft versus host disease. *Human Gene Therapy* 15:63-76
105. Caslini C, Serna A, Rossi V, **Introna M** and Biondi A (2004). Modulation of cell cycle by graded expression of MLL-AF4fusion oncoprotein, *Leukemia* 18:1064-71
106. Serafini M, Naldini L. and **Introna M** (2004). Molecular evidence of integration in a small fraction of proliferating human B lymphocytes transduced by VSV-pseudotyped HIV-1 derived lentivector. *Virology* 325:413-24
107. **Introna M**, Barbui AM, Golay J, Rambaldi A (2004). Innovative cell-based therapies in onco-hematology: what are the clinical facts ? *Haematologica* 89(10):1253-60.
108. **Introna M**, Rambaldi A (2004). Suicide gene therapy and the control of graft-vs-host disease. Review. *Best Pract Res Clin Haematol.*17(3):453-63.
109. Golay J, Manganini M, Rambaldi A, **Introna M** (2004). Effect of alemtuzumab on neoplastic B cells. *Haematologica* 89(12):1476-83.
110. Luchetti M.M, Sambo P, Majilingova P, Svegliati Baroni S, Peri G, Paroncini P, **Introna M**, Stoppacciaro A, Mantovani A, Gabrielli A (2004). Scleroderma fibroblasts constitutively express the long pentraxin PTX3. *Clin. Exp. Rheumatol.* 22:S66-72.
111. Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, Zelante L, Paolucci P, Biondi A, **Introna M**, Golay J (2005). Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. *Cancer Immunol Immunother.* 54(3):273-86.
112. Golay J, Di Gaetano N, Amico D, Cittera E, Barbui AM, Giavazzi R, Biondi A, Rambaldi A, **Introna M** (2005) Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. *Br J Haematol.* 128(3):310-7.

113. Barbui AM, Borleri G, Conti E, Ciocca A, Salvi A, Micò C, **Introna M**, Rambaldi A (2006). Clinical grade expansion of CD45RA, CD45RO, and CD62L positive T cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. *Exp. Hematol.*34: 475-485.
114. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, **Introna M** (2006). Complement is required for the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. *Haematologica* 91:176-83.
115. Golay J, Cortiana C, Manganini M, Cazzaniga G, Salvi A, Spinelli O, Bassan R, Barbui T, Biondi A, Rambaldi A, **Introna M** (2006). Acute lymphoblastic leukaemia cells carrying the t(12;21) translocation are highly sensitive to Campath-1H mediated cell lysis. *Haematologica* 91:322-330.
116. **Introna M**, Rambaldi A (2006). State of the art of cell based therapies in oncohematology: what are the clinical facts. *Organs, Tissues and Cells* 9 (2): 85-93.
117. **Introna M**, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, Rambaldi A (2006). Rapid and massive expansion of cord blood derived Cytokine Induced Killer (CIK) cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation, *Bone Marrow Transplantation* 38 (9): 621-627.
118. **Introna M**, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani E, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A (2007). Repeated infusions of donor-derived cytokine induced killer cells in patients relapsing after allogeneic stem cell transplantation: a Phase I study. *Haematologica*, 92(7):952-59.
119. Marin V, Dander E, Biagi E, **Introna M**, Fazio G, Biondi A, D'Amico G (2006). Characterisation of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy, *Experimental Hematology*, 34(9):1219-29.
120. Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, **Introna M**, Rambaldi A (2007). The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. *Leukemia*, 21(9):1892-1900.
121. Cittera E, Leidi M, Buracchi C, Pasqualini F, Sozzani S, Vecchi A, Waterfield JD, **Introna M**, Golay J (2007). The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. *J. Immunol.* 178(10):6616-6623.
122. Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A, Micò C, Rambaldi A, Golay J, **Introna M** (2007). Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. *Bone Marrow Transplantation*, 40(8):785-791.
123. Guerini V, Barbui V, Spinelli O, Salvi A, Della casa C, Carobbio A, **Introna M**, Barbui T, Golay J and Rambaldi A (2008). The Histone Deacetylase inhibitor ITF2357 Selectively Targets Cells Bearing Mutated JAK2^{V617F}, *Leukemia*, 22, 740-747.
124. Dander E, Pira GL, Biagi E, Perseghin P, Renoldi G, Gaipa G, **Introna M**, Marin V, Manca F, Biondi A, D'Amico G (2008). Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T cell lines expanded by a selective peptide library. *Exp. Hematol.* 36:473-85.
125. Golay J and **Introna M** (2008). Chemokines and antagonists in non-Hodgkin's lymphoma. *Expert Opin Ther Targets.* 12:621-35.

126. Morigi M, **Introna M**, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G (2008). Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. *Stem Cells* 26:2075-82.
127. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli MG, Palombo GA, **Introna M**, Golay J (2009). M2 macrophages phagocytose rituximab opsonised leukaemic targets more efficiently than M1 cells in vitro. *J. Immunol.* 182:4415-22.
128. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, **Introna M** (2009). Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. *Exp Hematol.* 37:616-628.
129. Capelli C, Salvade A, Pedrini O, Barbui V, Gotti E, Borleri G, Cabiati B, Belotti D, Perseghin P, Bellavita P, Biondi A, Biagi E, Rambaldi A, Golay J, **Introna M** (2009). [The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs.](#) *Cytotherapy* 11:403-13.
130. Dahlke MH, Hoogduijn M, Eggenhofer E, Popp FC, Renner P, Slowik P, Rosenauer A, Piso P, Geissler EK, Lange C, Chabannes D, Mazzanti B, Bigenzahn S, Bertolino P, Kunter U, **Introna M**, Rambaldi A, Capelli C, Perico N, Casiraghi F, Noris M, Gotti E, Seifert M, Saccardi R, Verspaget HW, van Hoek B, Bartholomew A, Wekerle T, Volk HD, Remuzzi G, Deans R, Lazarus H, Schlitt HJ, Baan CC; MISOT Study Group (2009). [Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.](#) *Transplantation* 88:614-9.
131. Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P, Rambaldi A, Neri A, **Introna M**, Lombardi L, Golay J (2010). [Pleiotropic anti-myeloma activity of ITF2357: inhibition of IL-6 receptor signalling and repression of miR-19a and miR-19b.](#) *Haematologica*, 95,2,260-269
132. Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberbi B, Abbate M, Zoja C, Cassis P, Longaretti L, Rebullia P, **Introna M**, Capelli C, Benigni A, Remuzzi G, Lazzari L (2010). Life-sparing effect of human cord blood mesenchymal stem cells in experimental acute kidney injury, *Stem Cells*, 28,3,513-522.
133. Slaper-Cortenbach I, Scott M, Herrmann D, **Introna M**, Theunissen K, Theocharous P, Chabannon C (2009). The regulatory situation for academic cell therapy facilities in Europe, in "Cell Therapy, cGMP facilities and manufacturing, ed A.Gee, Springer Science, 2009, pg 27-35.
134. **Introna M** and Golay J (2010). Complement in antibody therapy: friend or foe?, *Blood*, 114, 26, 5247-5248, 2009.
135. Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, **Introna M**, Pesenti E, Ciomei M, Golay J (2010). Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high burden leukaemia models. *Exp. Hematol*, 38,4,259-269.
136. Lucchini G, **Introna M**, Dander , Rovelli A, Balduzzi A, Bonanomi , Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Markt S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E (2010). Platelet Lysate expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft versus host disease in a pediatric population, *Biol Blood Marrow Transplant* 16(9):1293-301.
137. **Introna M**, Pievani A, Borleri G, Capelli C, Algarotti A, Micò C, Grassi A, Oldani E, Golay J, Rambaldi A (2010). Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. *Biol Blood Marrow Transplant.* 11:1603-7.
138. Perico N, Casiraghi F, **Introna M**, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasà M, Golay J, Noris M, Remuzzi G (2011). Autologous Mesenchymal Stromal Cells

and Kidney Transplantation: A Pilot Study of Safety and Clinical Feasibility. Clin J Am Soc Nephrol. 2011 February; 6(2): 412–422. doi: 10.2215/CJN.04950610

139. Pievani A, Belussi C, Klein C, Rambaldi A, Golay J, **Introna M** (2011). Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood 117:510-8.

140. Capelli C, Gotti E, Morigi M, Rota C, Weng L, Dazzi F, Spinelli O, Cazzaniga G, Rambaldi A, Golay J, **Introna M** (2011). Minimally manipulated whole human Umbilical Cord is a very rich source of clinical-grade hMSC expanded in human Platelet Lysate. Cytotherapy, 2011 Aug;13:786-801.

141. Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, **Introna M** (2010). Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 116:3372-3.

142. Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, **Introna M** (2011). Dual functional capability of CD3+/CD56+ CIK cells, a T cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118:3301-10.

143. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, **Introna M**, Golay J (2011). Mechanism of action of Type II glycoengineered anti-CD20 monoclonal antibody GA101 in B chronic lymphocytic leukaemia whole blood assays in comparison with Rituximab and Alemtuzumab. J. Immunol. 186:3762-9.

144. Amaru Calzada A, Todoerti K, Donadoni L, Pelliccioli A, Tuana G, Finazzi MG, Neri A, **Introna M**, Rambaldi A, Lombardi L, Golay J (2012). The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2^{V617F} myeloproliferative neoplasm cells. Exp. Hematol. 40:634-45.

145. Dander E, Lucchini G, Vinci P, **Introna M**, Masciocchi F, Perseghin P, Balduzzi A, Bonanomi S, Longoni D, Gaipa G, Belotti D, Parma M, Algarotti A, Capelli C, Golay J, Rovelli A, Rambaldi A, Biondi A, Biagi E, D'Amico G (2012). Mesenchymal stromal cells for the treatment of Graft-Versus-Host-Disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 26:1681-4.

146. Salvi M, Vannucchi G, Currò N, **Introna M**, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P (2012). Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. Jan;130:122-4

147. Golay J, **Introna M** (2012). Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. 526:146-53.

148. Lucchini G, Dander E, Pavan F, Di Ceglie I, Balduzzi A, Perseghin P, Gaipa G, Algarotti A, **Introna M**, Rambaldi A, Rovelli A, Biondi A, Biagi E, D'Amico G (2012). Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int. 2012;2012:690236..

149. Casiraghi F, Azzollini N, Cavinato R, Cassis P, Solini S, Rota C, Morigi M, **Introna M**, Maranta R, Perico N, Remuzzi G, Noris M (2012). Localization of mesenchymal stromal cells dictates their immune pro-inflammatory effects in kidney transplantation. Am J Transplant. 2012 Sep;12(9):2373-83.

150. Amaru Calzada A, Pedrini O, Finazzi G, Leoni F, Mascagni P, **Introna M**, Rambaldi A, Golay J *on behalf of the AGIMM Investigators* (2012). Givinostat and Hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2^{V617F} Myeloproliferative Neoplasm patients. Exp. Hematol. 40:634-45.

151. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, **Introna M**, Golay J (2013). Ofatumumab is more efficient than Rituximab in lysing B-CLL cells in whole blood and in combination with chemotherapy. *J. Immunol.* 190:231-9
152. Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, **Introna M**, Pesenti E, Alzani R (2013). The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. *PLoS One* 8:e58424.
153. Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, Capelli C, Introna M, Remuzzi G, Benigni A (2013). Transfer of growth factor receptor mRNA via exosome unravels some secrets of the regenerative effect of mesenchymal stem cells. *Stem Cells Dev* 22:772-80.
154. Franquesa M, Hoogduijn MJ, Reinders ME, Eggenhofer E, Engela AU, Mensah FK, Torras J, Pileggi A, van Kooten C, Mahon B, Detry O, Popp FC, Benseler V, Casiraghi F, Johnson C, Ancans J, Fillenberg B, delaRosa O, Aran JM, Roemeling-van Rhijn M, Pinxteren J, Perico N, Gotti E, Christ B, Reading J, **Introna M**, Deans R, Shagidulin M, Farré R, Rambaldi A, Sanchez-Fueyo A, Obermajer N, Pulin A, Dor FJ, Portero-Sanchez I, Baan CC, Rabelink TJ, Remuzzi G, Betjes MG, Dahlke MH, Grinyó JM; MiSOT Study Group (2013). Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials. *Transplantation* 96:234-8
155. **Introna M**, Golay J, Rambaldi A (2013). Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. *Immunol Lett.* 155:27-30
156. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, **Introna M** (2013). Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. *Blood.* 122:3482-91
157. Olivieri J, Pierelli L, **Introna M**, Accorsi P, Bosi A, Perseghin P, Rizzo M, Pandolfi A, Mancini S, Marchetti M, Dal Pozzo S, Gotti E, Rambaldi A, Leoni P, Olivieri A; Gitmo (Gruppo Italiano Trapianto di Midollo Osseo) -SIDEM (Società Italiana di Emaferesi e Manipolazione Cellulare) Working Group on SCU Disposal (2013). Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. *Cytotherapy.* 16:101-10.
158. **Introna M**, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D'Amico G, Biondi A, Rambaldi A, Biagi E (2013). Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. *Biol Blood Marrow Transplant.* S1083-8791(13)00570-3
159. Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, D'Anca M, Pellegrino E, Piva R, Inghirami G, Capelli C, **Introna M**, Baldini L, Chiaramonte R, Lombardi L, Neri A (2013). Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. *Genes Chromosomes Cancer* 53:154-67
160. Perico N, Casiraghi F, Gotti E, **Introna M**, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Noris M, Remuzzi G (2013). Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. *Transpl Int.* 2013 Sep;26(9):867-78. doi: 10.1111/tri.12132. Epub 2013 Jun 6.
161. Golay J, D'Amico A, Borleri G, Finazzi MC, Quaresmini G, Nagorsen D, **Introna M**, Rambaldi A (2014). A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. *J. Immunol.* 193(9):4739-47.

162. Perseghin P, Marchetti M, Pierelli L, Olivieri A, **Introna M**, Lombardini L, Accorsi P, Petrini C, Risso M, Bosi A (2014). A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. Società Italiana di Emaferesi e Manipolazione Cellulare,; Gruppo Italiano Trapianto Midollo Osseo; Centro Nazionale Trapianti. *Transfusion* 54(9):2353-60.
163. Valgardsdottir R, Capitanio C, Texido G, Pende D, Cantoni C, Pesenti E, Rambaldi A, Golay J, **Introna M** (2014). Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. *Exp Hematol.* 42(12):1013-1021
164. Capelli C, Pedrini O, Cassina G, Spinelli O, Salmoiraghi S, Golay J, Rambaldi A, Giussani U, **Introna M** (2014). Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. *Haematologica.* 99(6):e94-7. doi: 10.3324/haematol.2014.104711.
165. Da Roit F, Engelberts PJ, Taylor RP, Breij ECW, Gritti G, Rambaldi A, **Introna M**, Parren PWHI, Frank J, Beurskens FJ, Golay J (2015). Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy. *Haematologica* 100(1):77-86.
166. **Introna M**, Rambaldi A (2015). Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. *Curr Opin Organ Transplant.* 20(1):72-8.
167. Rambaldi A, Biagi E, Bonini C, Biondi A, **Introna M** (2015). Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. *Leukemia.* 29(1):1-10.
168. Todeschi MR, El Backly R, Capelli C, Daga A, Patrone E, **Introna M**, Cancedda R, Mastrogiacomo M (2015). Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration. *Stem Cells Dev* 24(13):1570-81. doi: 10.1089/scd.2014.0490.
169. Papadimou E, Morigi M, Iatropoulos P, Xinaris C, Tomasoni S, Benedetti V, Longaretti L, Rota C, Todeschini M, Rizzo P, **Introna M**, Grazia de Simoni M, Remuzzi G, Goligorsky MS, Benigni A (2015). Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts. *Stem Cell Reports* 4(4):685-98.
170. Capelli C, Pedrini O, Valgardsdottir R, Da Roit F, Golay J, **Introna M** (2015). Clinical grade expansion of MSCs. *Immunol Lett.* 168(2):222-7. doi: 10.1016/j.imlet.2015.06.006.
171. Violatto MB, Santangelo C, Capelli C, Frapolli R, Ferrari R, Sitia L, Tortarolo M, Talamini L, Previdi S, Moscatelli D, Salmona M, **Introna M**, Bendotti C, Bigini P (2015). Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. *Stem Cell Res.* 15(1):243-53. doi: 10.1016/j.scr.2015.06.010.
172. Fiocchi R, D'Elia E, Vittori C, Sebastiani R, Strobelt N, Eleftheriou G, **Introna M**, Freddi C, Crippa A (2015). First Report of a Successful Pregnancy in an Everolimus-Treated Heart-Transplanted Patient: Neonatal Disappearance of Immunosuppressive Drugs. *Am J Transplant.* doi: 10.1111/ajt.13514.
173. Gaipa G, **Introna M**, Golay J, Nolli ML, Vallanti G, Parati E, Giordano R, Romagnoli L, Melazzini M, Biondi A, Biagi E (2016). Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. *Cytotherapy.* 2016 Apr;18(4):481-6. doi: 10.1016/j.jcyt.2016.01.002

174. Belotti D, Capelli C, Resovi A, **Introna M**, Taraboletti G (2016). Thrombospondin-1 promotes mesenchymal stromal cell functions via TGF β and in cooperation with PDGF. *Matrix Biol.* 2016 Mar 16. pii: S0945-053X(16)30026-9. doi: 10.1016/j.matbio.2016.03.003. [Epub ahead of print]
175. Capelli C, Zaccara E, Cipriani P, Di Benedetto P, Maglione W, Andracco R, Di Luca G, Pignataro F, Giacomelli R, **Introna M**, Vitali C, Del Papa N (2017). Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systemic Sclerosis. *Cell Transplant.* 2017 May 9;26(5):841-854. doi: 10.3727/096368917X694822. Epub 2017 Jan 31.
176. Valgardsdottir R, Cattaneo I, Klein C, **Introna M**, Figliuzzi M, Golay J (2017). Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. *Blood.* 2017 May 11;129(19):2636-2644. doi: 10.1182/blood-2016-08-735605. Epub 2017 Mar 13.
177. Golay J, Ubiali G, **Introna M** (2017). The specific BTK inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B-cells with CD20 antibodies. *Haematologica.* 2017 Jun 22. pii: haematol.2017.169334. doi: 10.3324/haematol.2017.169334.
178. **Introna M** (2017). CIK as therapeutic agents against tumors. *J Autoimmun.* 2017 Jul 2. pii: S0896-8411(17)30413-4. doi: 10.1016/j.jaut.2017.06.008.
179. **Introna M**, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Micò C, Grassi A, Pavoni C, Ferrari ML, Delaini F, Todisco E, Cavattoni I, Deola S, Biagi E, Balduzzi A, Rovelli A, Parma M, Napolitano S, Sgroi G, Marrocco E, Perseghin P, Belotti D, Cabiati B, Gaipa G, Golay J, Biondi A, Rambaldi A (2017). Phase II Study of Sequential Infusion of DLI and Cytokine Induced Killer Cells for Patients Relapsed after alloHSCT. *Biol Blood Marrow Transplant* 23 (2017) 2070–2078 pii: S1083-8791(17)30574-8. doi: 10.1016/j.bbmt.2017.07.005.
180. Perico L, Morigi M, Rota C, Breno M, Mele C, Noris M, **Introna M**, Capelli C, Longaretti L, Rottoli D, Conti S, Corna D, Remuzzi G, Benigni A (2017). Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. *Nature Communications.* 2017 Oct 17;8(1):983. doi: 10.1038/s41467-017-00937-2.
181. Strunk D, Lozano M, Marks DC, Loh YS, Gstraunthaler G, Schennach H, Rohde E, Laner-Plamberger S, Öller M, Nystedt J, Lotfi R, Rojewski M, Schrezenmeier H, Bieback K, Schäfer R, Bakchoul T, Waidmann M, Jonsdottir-Buch SM, Montazeri H, Sigurjonsson OE, Iudicone P, Fioravanti D, Pierelli L, **Introna M**, Capelli C, Falanga A, Takanashi M, López-Villar O, Burnouf T, Reems JA, Pierce J, Preslar AM, Schallmoser K. (2017). International Forum on GMP-grade human platelet lysate for cell propagation: summary. *Vox Sanguinis* 2017 Oct 26. doi: 10.1111/vox.12593.
182. Sironi F, Vallarola A, Violatto MB, Talamini L, Freschi M, De Gioia R, Capelli C, Agostini A, Moscatelli D, Tortarolo M, Bigini P, **Introna M**, Bendotti C (2017). Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. *Stem Cell Res.* 2017 Nov 10;25:166-178. doi: 10.1016/j.scr.2017.11.005.
183. Golay J, Pedrini O, Capelli C, Gotti E, Borleri G, Magri M, Vailati F, Passera M, Farina C, Rambaldi A, **Introna M** (2018). Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. *Cytotherapy.* 2018 Feb;20(2):262-270. doi: 10.1016/j.jcyt.2017.11.009
184. **Introna M**, Correnti F (2018). Innovative Clinical Perspectives for CIK Cells in Cancer Patients. *International journal of molecular sciences* 19 (2), 358

185. Perseghin P, Laszlo D, Bonifazi F, **Introna M**, Accorsi P, Petrini C, Lombardini L (2018). Disposal of the residual autologous HSC units: Results of a survey carried out two years after the publication of a national policy in Italy. *Transfus Apher Sci.* 2018 Apr;57(2):197-200.
186. Perico N, Casiraghi F, Todeschini M, Cortinovis M, Gotti E, Portalupi V, Mister M, Gaspari F, Villa A, Fiori S, **Introna M**, Longhi E, Remuzzi G (2018). Long-term Clinical and Immunological Profile of Kidney Transplant Patients given Mesenchymal Stromal Cell Immunotherapy. *Frontiers in Immunology* 9, 1359
187. Moroncini G, Paolini C, Orlando F, Capelli C, Grieco A, Tonnini C, Agarbati S, Mondini E, Saccomanno S, Goteri G, Svegliati Baroni S, Provinciali M, **Introna M**, Del Papa N, Gabrielli A (2018). Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. *PLoS One.* 2018 Jun 1;13(6):e0196048.
188. Golay J, Martinelli S, Alzani R, Cribioli S, Albanese C, Gotti E, Pasini B, Mazzanti B, Saccardi R, Rambaldi A, **Introna M** (2018). Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. *Cytotherapy.* 2018 Aug;20(8):1077-1088.
189. Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, **Introna M**, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F (2018). Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2018 Nov;24(11):2365-2370.
190. Mico' M, Algarotti A, Grassi A, Pavoni C, Onida F, Mordini N, Ferrari ML, Lussana F, Finazzi MC, Taurino D, Capelli C, **Introna M**, Rambaldi A (2018). Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. *Blood* 2018 132:3404.
191. Rota C, Morigi M, Cerullo D, **Introna M**, Colpani O, Corna D, Capelli C, Rabelink TJ, Leuning DG, Rottoli D, Benigni A, Zoja C, Remuzzi G (2018). Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. *Stem Cell Res Ther.* 2018 Aug 14;9(1):220.
192. Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, **Introna M** (2019). Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation. *Blood.* 2019 Jan 17. pii: blood-2018-07-864538.
193. Orlando F, Paolini C, Agarbati S, Tonnini C, Grieco A, Capelli C, **Introna M**, Provinciali M, Gabrielli A, Moroncini G (2019). Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin. *J Vis Exp.* 2019 Apr 30;(146).
194. Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. Collaborators: Laroni A, Uccelli A, Bonetti B, Rush C, Herrera C, Ramo Tello C, Miller D, Szwajcer D, Strunk D, Wall D, Aguera-Morales E, Radue EW, Rohde E, Dazzi F, Comi G, Martino G, Izquierdo Ayuso G, Rabinovitch H, MacLean H, Marriott J, Wuerfel JT, Sellner J, Racosta J, Arab L, Brundin L, Sormani MP, Battaglia MA, Gimona M, Freedman MS, **Introna M**, Clanet M, Blinkenberg M, Aghdami N, Fernández Ó, Muraro PA, Soelberg Sorensen P, Ali R, Vosoughi R, Nicholas R, Oliveri RS, Marrie RA, Nabavi SM, Karimi S (2019). MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. *Trials.* 2019 May 9;20(1):263.

195. Lee R, Del Papa N, **Introna M**, Reese CF, Zemsanova M, Bonner M, Carmen-Lopez G, Helke K, Hoffman S, Tourkina E (2019). Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1. *JSRD* 2019, 4(2) 127-136
196. S Agarbati, G Moroncini, C Paolini, F Orlando, C Capelli, A Grieco, C Tonnini, E Mondini, S Saccomanno, G Goteri, S Svegliati Baroni, M Provinciali, **M Introna**, N Del Papa, A Gabrielli. 2019. Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. *EUROPEAN JOURNAL OF IMMUNOLOGY* 49, 263-264
197. D Taurino, M Mico, A Algarotti, A Grassi, C Pavoni, F Onida, N Mordini, ML Ferrari, F Lussana, MC Finazzi, C Capelli, **M Introna**, A Rambaldi. 2019. Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. *Haematologica* 104 19-19.
198. Casiraghi F, Perico N, Gotti E, Todeschini M, Mister M, Cortinovis M, Portalupi V, Plati AR, Gaspari F, Villa A, **Introna M**, Longhi E, Remuzzi G (2020). Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. *Stem Cells Transl Med.* 2020 Apr;9(4):427-432.

BOOKS -LIBRI

1. Mantovani A, Peri G, Polentarutti N, Allavena P, Introna M, Sessa C, Mangioni C.: Tumor-associated macrophages and lymphoid cells in human ovarian carcinoma: Modulation of their tumoricidal capacity by immunopharmacologic agents. In: "Meditation of Cellular Immunity in Cancer by Immune Modifiers", M. A. Chirigos, M. Mitchell, M. J. Mastrangelo, M. Krim eds, Progress in Cancer Research, Vol 19, Raven Press, New York, pp. 181-192, 1981.
2. Bordignon C, Allavena P, Introna M, Biondi A, Bottazzi B, Mantovani A: Modulation of NK activity by human mononuclear phagocytes: Suppressive activity of broncho-alveolar macrophages. In: "NK Cells and Other Natural Effector Cells", R. B. Herberman ed, Academic Press, New York, pp. 581-588, 1982.
3. Introna M, Allavena P, Acero R, Colombo N, Molina P, Mantovani A: Natural Killer activity in human ovarian tumors. In: "NK Cells and Other Natural Effector Cells ", R.B. Herberman ed, Academic Press, New York, pp. 119-126, 1982.
4. Mantovani A, Biondi A, Introna M, Bottazzi B, Polentarutti N, Bordignon C.: Human macrophage populations with different tumoricidal and immunoregulatory activity. Functional status of tumor-associated inflammatory cells. In: "Current Concepts in Human Immunology and Cancer Immunomodulation ", B. Serron, C. Rosenfeld, J. C. Daniels and J. P. Saunders, Eds, Elsevier, Amsterdam, pp. 257-262, 1982.
5. Mantovani A, Bordignon C, Biondi A, Introna M, Allavena P.: Citotoxicity on tumor cells of human macrophages: Functional status of tumor-associated effector cells. *Adv Exp Med Biol* 141: 99-107, 1982.
6. Mantovani A, Allavena P, Biondi A, Sessa C, Introna M: NK activity in human ovarian carcinoma. In: "Natural Killer Cells: fundamental aspects and role in cancer ", B. Serrou, C. Rosenfeld, R. B. Herberman eds, Elsevier, Amsterdam, p. 123-137, 1982.
7. Colotta F, Rambaldi A, Introna M, Colombo N, Mantovani A.: Effect of a streptococcal preparation (OK432) on natural cytotoxicity in human ovarian carcinoma. In: "Natural Killer Activity and its Regulation", T. Hoshino, H. S. Koren, A. Uchida, Eds, Excerpta Medica, pp. 227-230, 1984.

8. Rambaldi A, Colotta F, Introna M, Peri G, Fasan M, Rossi V, Colombo N, Mangioni C, Mantovani A.: Preliminary studies on the intraperitoneal administration of B-interferon (IFN) in patients with ovarian carcinoma ascites. In: "Natural Killer Activity and its Regulation" T. Hoshino, H. S. Koren, A. Uchida, Eds, Excerpta Medica, pp. 447-451, 1984.
9. Introna M, Bordignon C, Molinari A, Vicenzi E, Ghezzi P, Salmona M, Donati M. B, Maruzzi M, Mantovani A: Analysis of inhibition of NK activity by human mononuclear phagocytes. In "Natural Killer Activity and its Regulation", T. Hoshino, H. S. Koren, A. Uchida, Eds, Excerpta Medica, pp. 270-275, 1984.
10. Rambaldi A, Allavena P, Introna M, Zanaboni F, Rossi V, Bassan R, Barbui T, Mantovani A.: T lymphoproliferative disorders: studies on cytotoxic activity, membrane antigens expression and lymphokine production. "New Trends in Experimental Hematology"; Eds. C. Peschle and C. Rizzoli. Ares-Serono Symposia, vol. 7, pp. 499-504, 1984.
11. Introna M, Bast R. C. Jr, Epithelial ovarian carcinoma: Cell lines and antigenic tumor markers. In: Cancer of the Female Reproductive System, eds. J. M. A. Whitehouse and C. J. Williams. Sussex: John Wiley, pp 153-180, 1985.
12. Poli G, Taraboletti G, Zanaboni F, Bottazzi B, Introna M, Mantovani A. In : Situ versus systemic expression of natural resistance in tumors, in: "From oncogenes to tumor antigens" edited by Giraldo G, Beth E, Castello G, Giordano G. G, Zarrilli D, Elsevier Science Publisher, pp. 185-190, 1985.
13. Introna M, Golay J. (1992). The role of oncogenes in myeloid differentiation. In "Development, the Molecular Genetic Approach ", Russo V.E.A , Brody S, Cove D. and Ottolenghi S. eds, Springer Verlag, pp. 499-503.
14. Introna M, Golay J. and Ottolenghi S. (1992). Cellular Differentiation in the Hematopoietic System: An Introduction. In "Development, the Molecular Genetic Approach " , Russo V.E.A, Brody S, Cove D. and Ottolenghi S. eds, Springer Verlag, pp. 504-518.
15. Introna M, Breviario F, D'Aniello E.M, Dejana E. and Mantovani A. Modulation of endothelial cell function by cytokines. In Vascular Endothelium: Physiological Basis of Clinical Problems, vol. 2, J.D. Catravas ed, Plenum Press, N.Y, pp. 107-114, 1993.
16. Introna M, Breviario, F, D'Aniello E, Luchetti M.M, Alles V.V, Dejana E. and Mantovani A. Cytokine regulation of endothelial cell function. Boehring Institut Mitteilungen,92,23-29,1993.
17. Introna,M, Colotta,F, Sozzani,S, Dejana,E, Mantovani,A. (1994) Pro and anti-inflammatory cytokines: interactions with vascular endothelium. Clin.Exp.Rheumatol, 12,S19-S23, 1994.
18. Duperray,A, Mantovani,A, Introna,M, Dejana,E. (1995) Endothelial cell regulation of leukocyte infiltration in inflammatory tissues ; in: Mediators of inflammation, 4, 322-330. Rapid Science Publishers
19. Introna,M, Vidal Alles,V, Picardi,G, Basile,A, Matteucci,C, Bottazzi,B, Peri,G, D'Aniello,E.B, Breviario,F, Mantovani,A. (1996) Cytokine activation of endothelium: cloning and characterization of a new IL-1 inducible gene in: Vascular endothelium; responses to injury, edited by J.D.Catravas, A.D.Callow, U.S.Ryan, NATO Advanced Study Institute, vol.281, Plenum Press, N.Y, 1996, 139-144.
20. Allavena P, Bianchi G, Giardino G, Polentarutti N, Zhou D, Introna M, Sozzani S, Mantovani A. (1996) Migratory response of human NK cells to monocyte-chemotactic proteins, in METHODS: A companion to Methods in Enzymology 10, 145-149, Academic Press.

21. Mantovani, A, Dejana, E, Bussolino, F, Introna, M. (1997) Cytokines and endothelial cells. in: cytokines in health and disease, ed. J.S. Friedland and D.G. Remnick; Marcel Dekker, Inc. New York. Basel. Hong Kong. 323-337.
22. Mantovani A, Sozzani S, Introna M. (1997) Endothelial activation by cytokines, Ann. N.Y. Acad. Sci, 1997, vol.832, 93-116, eds R. Paoletti, A. Notario, G. Ricevuti, The New York Academy of Sciences, New York, New York.
23. Mantovani A, Allavena P, Vecchi A, Dejana E, Sozzani S, Introna M. (1998) Cytokine regulation of endothelial cell function. in: vascular endothelium. Pharmacologic and genetic manipulation. Plenum Press, New York; 1998, 105-134
24. Mantovani A, Muzio M, Ghezzi P, Colotta F, Introna M. (1998) Regulation of inhibitory pathways of the the interleukin-1 system: Ann.N.Y.Acad.Sci. 1998, 840: 338-351.
25. Spinelli O, Caslini C, Cazzaniga G, Golay J, Amaru R, Barbui T, Biondi A, Introna M, Rambaldi A. New isoforms of the ZFM1 gene: a growing family of signal transduction and activator of RNA (STAR) proteins (1998) in: Acute Leukemias VII, Experimental approaches and novel therapies, W. Hiddemann, T. Buchner, B. Wormann, J. Ritter, U. Creutzig, M. Keating, W. Plunkett eds, Springer-Verlag Berlin Heidelberg, 190-198.
26. Mantovani A, Garlanda C, Introna M, Vecchi A. (1998) Regulation of endothelial cell function by pro- and anti-inflammatory cytokines. Transplant. Proc. 30: 4239-4243.
27. Golay J, Introna M. (1999) Structural and functional properties of CD20, a target of therapeutic antibodies. In Recent Research Development In Immunology 1999. 1, 559-567.
28. Introna M. (2004) Il trapianto di midollo osseo come immunoterapia: storia e prospettive. in "Cellule e Genomi 3° corso", Casa Editrice Studia Ghisleriana, Pavia, p.235-244.
29. Golay J, Introna M. (2005) Anticorpi per la immunoterapia dei tumori: successi, limiti e prospettive. Collana Quaderni di Argon, casa editrice Medical Communications. pp 109.
30. Introna M, Rambaldi A. (2005) Terapie Immunologiche: Il trapianto di midollo osseo. Collana Quaderni di Argon, casa editrice Medical Communications. pp:127.
32. Introna M. (2005) Le terapie cellulari e geniche per il miglioramento del trapianto di midollo osseo. Libro degli Atti del 40° Congresso Nazionale Società Italiana Ematologia 2005. Review pp. 208-213.
33. Introna M (2005) Cellule staminali e riparazione d'organo. Oncology & Hematology Review 11:49-54. Editors Aversa F, Baccarani M, Barbui T, Ferrara F, Gobbi M. Momento Medico, Salerno, Italy.
34. Introna M, and Golay J. (2005) Mechanism of action of therapeutic monoclonal antibodies. Hematology - The European Hematology Association Program 1:151-155
35. Golay J and Introna M. (2012) Anticorpi Monoclonali Terapeutici in Oncoematologia. In Seminari in Ematologia. Ed. Lambertenghi Delilieri Edizioni Internazionali srl
36. Introna M, Golay J. (2015) Prodotti Medicinali di Terapia Avanzata (ATMP): un difficile equilibrio tra i bisogni clinici e la sostenibilità dell'adeguamento alle normative vigenti. Informazione sui farmaci anno 39, n°3, 2015